Abstract
Although many treatment options have been adopted in patients with metastatic hormone sensitive prostate cancer (mHSPC), such as early docetaxel and AR-targeting therapy, there are currently no optimal biomarkers to guide treatment in these patients. Here, we sought to define transcriptomic landscape in mHSPC patients treated by either early docetaxel or abiraterone acetate by performing RNA sequencing.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
